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Non–small cell lung cancer (NSCLC) patients have very low survival rates because the current therapeutic
strategies are not fully effective. Although EGFR tyrosine kinase inhibitors are effective for NSCLC patients
harboring EGFR mutations, patients invariably develop resistance to these agents. Alterations in multiple signaling
cascades have been associated with the development of resistance to EGFR inhibitors. Sonic Hedgehog and
associated Gli transcription factors play a major role in embryonic development and have recently been found to
be reactivated in NSCLC, and elevated Gli1 levels correlate with poor prognosis. The Hedgehog pathway has been
implicated in the functions of cancer stem cells, although the underlying molecular mechanisms are not clear. In
this context, we demonstrate that Gli1 is a strong regulator of embryonic stem cell transcription factor Sox2.
Depletion of Gli1 or inhibition of the Hedgehog signaling significantly abrogated the self-renewal of stem-like side-
population cells from NSCLCs as well as vascular mimicry of such cells. Gli1 was found to transcriptionally
regulate Sox2 through its promoter region, and Gli1 could be detected on the Sox2 promoter. Inhibition of
Hedgehog signaling appeared to work cooperatively with EGFR inhibitors in markedly reducing the viability of
NSCLC cells as well as the self-renewal of stem-like cells. Thus, our study demonstrates a cooperative functioning
of the EGFR signaling and Hedgehog pathways in governing the stem-like functions of NSCLC cancer stem cells
and presents a novel therapeutic strategy to combat NSCLC harboring EGFR mutations.
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Lung cancer is the leading cause of cancer related deaths in the United
States [1]. Although non–small cell lung cancer (NSCLC) patients
with early-stage disease are treated by surgery, about 30% to 60%
develop recurrent tumors, which result in mortality [2,3]. Chemo-
therapeutic agents like gemcitabine, platinum compounds, and
taxanes improve survival to a limited extent, but overall survival
rates remain low because of recurrence of more aggressive,
drug-resistant tumors [4,5]. NSCLC in non-smokers show predom-
inantly mutations in EGFR [6]; such patients respond well to EGFR
inhibitors like erlotinib but eventually develop resistance and
succumb to the disease [7]. In all the cases, the recurrence can be
local or metastatic, and commonly occur after a period of clinical
dormancy [2]. Resistance to EGFR inhibitors occurs through various
mechanisms, including the appearance of the T790M gatekeeper
mutation, expression of c-Met gene, or activation of alternatesignaling pathways [8,9]. Development of strategies to combat
resistance to EGFR inhibitors in NSCLC will be of immense benefit
to a large number of patients [10].A
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tumor, have been proposed to be responsible for the initiation and
progression of a variety of cancers, including NSCLC [11–13]. CSCs
from NSCLC cell lines, tumor samples, and mouse models have been
isolated based on various markers including ALDH1, side-population
phenotype, and CD133 positivity [14–16]. CSCs are slow-dividing
cells that are highly drug resistant, and it has become clear that
targeting such cell population would be imperative to combat
NSCLC. The absence of effective therapy is related to the complexity
of CSCs, and therefore better understanding of the biology of CSCs is
a requisite.
The developmental pathways associated with lung including the
Hedgehog (Hh) signaling pathway have been shown to promote the
genesis and progression of human cancers [17]. Three Hh genes exist
in mammals, namely, Sonic Hedgehog (Shh), Desert Hedgehog
(Dhh), and Indian Hedgehog (Ihh); of these, Shh is the most widely
expressed [17–19]. Elucidation of the Hh signaling pathway showed
that secreted Shh binds to the receptor Patched (Ptch) present on the
cell membrane, releasing the Ptch-mediated repression of Smooth-
ened, which is a seven-pass transmembrane spanning protein essential
for the transduction of Hh signaling [17,20]. Smoothened facilitates
the interaction of different Hh downstream effectors resulting in the
activation of the Gli transcription factors. In humans, the three Gli
proteins, Gli1, Gli2, and Gli3, coordinate specific Hh responses in
the cell by modulating gene expression [17,18,20,21]. Genes of the
Hh pathway including Gli1 and Ptch1 are targets of Gli, therefore
representing a feedback loop; furthermore, Gli3 is thought to repress
Gli1-mediated transcription, while Gli2 is thought to upregulate Gli1
function [20,21].
The Hh pathway has also been implicated in regulation of CSCs in
various cancers and is known to increase tumor invasiveness [22–24].
Our earlier studies have shown that side-population (SP) cells isolated
by Hoechst 33342 exclusion from multiple NSCLC cell lines and
human tumor explants have CSC-like properties [25,26]. SP cells
could self-renew and form spheres in low-adherence plates and initiate
tumors in mice; furthermore, a gene expression profile derived from
these stem-like cells correlated with poor prognosis [27]. The
self-renewal properties of stem-like SP cells were driven mainly by the
embryonic stem cell transcription factor Sox2, whereas Oct4 and
Nanog appeared to play a lesser role [26]. We have found that Sox2
levels were regulated by EGFR signaling cascades; inhibition of EGFR
significantly reduced the expression of Sox2 and abrogated self-
renewal of SP cells [26]. Our earlier work also showed that Sox2 levels
were elevated in progressed, metastatic adenocarcinomas; such a
correlation was not found in squamous cell carcinomas [26]. Other
groups have shown that Hh and EGFR can cooperatively regulate
multiple genes including Sox2 in basal cell carcinoma [28]. Given the
importance of Sox2 in facilitating stem-like properties of CSCs, the
present study attempts to investigate the Hh pathway–mediated
regulation of Sox2 expression in NSCLC cells, especially in stem-like
cells. Components of the Hh pathway are altered in human NSCLC,
and their expression predicts poor prognosis. Our experiments also
show that inhibition of the Hh pathway using the Smoothened
inhibitors GDC-0449 or BMS-833923 (XL139) abolished the
self-renewal of SP cells. Depletion of Gli1, the major mediator of
Hh function, led to a reduction in the levels of Sox2 and significantly
abrogated the self-renewal of SP cells as well as their ability to form
angiogenic tubules that represent vascular mimicry. Interestingly, Hh
pathway inhibitors appeared to enhance the growth-suppressiveproperties of EGFR inhibitors and depletion of Gli1-sensitized NSCLC
cells to erlotinib and gefitinib.We believe that these studies will shed light
on novel mechanisms underlying the genesis of NSCLC and will lead to
the identification of novel therapeutic modalities to combat NSCLC by
overcoming resistance to EGFR inhibitors.
Materials and Methods
Cells and Reagents
All the four human NSCLC cell lines, H1650, HCC827, PC-9,
and H1975, were purchased from ATCC and maintained in RPMI
1640 (Gibco, Life Technologies) supplemented with 10% fetal
bovine serum (Atlas Biologicals). The H1650, HCC827, and PC-9
cell lines harbor deletion ΔE746-A750 in the exon 19 of EGFR
tyrosine kinase receptor. The H1975 harbors L858R mutation and
additionally T790M mutation in the EGFR receptor. The
drug-resistant HCC827-ER cell line was maintained in culture
media with 1μM erlotinib, and PC-9-GR was maintained in culture
media with 1μM gefitinib. All the cultures were maintained at 5%
CO2 at 37°C. Human EGF (E9644-2MG) was purchased from
Sigma-Aldrich. Recombinant Human SHH N-Terminus
(1845-SH-025) was purchased from R&D Systems. Gefitinib
(G4408), erlotinib (E-4007), and BIBW (A-8644) were purchased
from LC Laboratories. GDC-0449 (S1082) and BMS-833923 (S7138)
were purchased from Selleck Chemicals.
Antibodies
The antibodies used are as follows: Sox2 (#3579), Oct4 (# 2750),
Nanog (#4903), acetylated histone H3 Lysine 9 (# 9671), and Gli1
(#2643) were from Cell Signaling Technologies; mouse monoclonal
antibody to actin was from Sigma-Aldrich; Gli2 (SC-271786) was
purchased from Santa Cruz Biotechnologies; and Gli3 antibody
(Ab55437) was from Abcam.
Isolation of SP Cells and ALDHhigh Cells
For isolation of SP cells, asynchronously growing cells were
harvested using Accutase reagent (Sigma Aldrich), washed once with
PBS, and resuspended in Dulbecco’s modified Eagle’s medium:F12K
medium (Gibco, Life Technologies) with 2% FBS at 1 × 106 cells/ml
density. Cells were then incubated with 4 μg/ml of Hoechst 33342
dye (Life Technologies) for 90 minutes at 37°C in the presence or
absence of 1 μM Fumitremorgin C (Sigma Aldrich) [15,25,26].
The Aldefluor assay kit (Stem cell Technologies) was used to isolate
ALDHhigh cells as per manufacturer’s protocol. In brief, cells were
suspended in Aldefluor assay buffer containing Aldefluor substrate
(1 μM) at 1 × 10 6 cells/ml density and incubated at 37°C for
45 minutes. To sort the Aldhhigh and Aldhlow population, the gates were
set relative to baseline fluorescence determined by addition of
Aldh-specific inhibitor diethylaminobenzaldehyde from the assay kit.
Both Hoechst- and Aldefluor-stained cells were sorted using FACS
Vantage (BDFACSDiVa) cell sorter as described in previous publications
[25,26]. Data analyses were done using the FlowJo software (Tree Star).
Sphere Formation Assay for Self-Renewal
The sorted cells (SP or Aldhhigh) were plated in ultra-low attachment
96-well plate (Corning Inc.) at a density of 10,000 cells/ml (1000 cells/
100 μl/well) in stem cell selective medium [Dulbecco’s modified Eagle’s
medium:F12K (1:1) supplementedwithN2 supplement (1×) (Invitrogen),
10 ng/ml EGF, and 10 ng/ml bFGF (Sigma Aldrich)] at 37°C for
10 days [25,26]. The spheres were observed using an automated Zeiss
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AxioCam MRm3 CCD camera and Axiovision version 4.7 (Carl Zeiss
Inc., Germany). The numbers of spheres greater than or equal to 50 μm
were counted. To study the effect of the drugs on the self-renewal ability
of SP cells, the appropriate concentrations were added to the respective
wells on Day 0 and Day 5, and the size and number of the spheres were
analyzed onDay 10. The sphere formation assays were performed twice
with triplicates of each treatment in every assay.
RNA Isolation and Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR) Analysis
Total RNA was isolated from the cells by RNeasy Miniprep kit
from Qiagen following the manufacturer’s protocol. One microgram
of RNA was converted into cDNA using iScript cDNA synthesis kit
(Bio-Rad). Levels of mRNA were analyzed using qRT-PCR that was
performed using Bio-Rad CFX96 Real-Time system. Data were
normalized using GAPDH as an internal control, and fold change was
calculated by 2−ΔΔCt method. The primers are as follows:
Gli1 FP 5'-CCCAATCACAAGTCAGGTTCCT-3',
Gli1 RP 5'-CCTATGTGAAGCCCTATTTGCC-3',
Gli2 FP 5'-TGCACCAAGGAGTACGACAC-3',
Gli2 RP 5'-AGCATGTACTGCGCCTTGAA-3',
Gli2 FP 5'-TGCACCAAGGAGTACGACAC-3',
Gli2 RP 5'-AGCATGTACTGCGCCTTGAA-3',
FoxM1 FP 5'-TTTATCAGTGCTGCTAGCTGAGG-3',
FoxM1 RP 5'-TCTGAACTGGAAGCAAAGGAGA-3',
ABCG2 FP 5'-CACAAGGAAACACCAATGGCT-3',
ABCG2 RP 5'-ACAGCTCCTTCAGTAAATGCCTTC-3',
ALDH1 FP 5'-CCGCAAGACAGGCTTTTCAG-3',
ALDH1 RP 5'-CATTGTCGCCAGCAGCAGA-3',
Sox2 FP 5'-GGGAAATGGGAGGGGTGCAAAAGA-3',
Sox2 RP 5'-TTGCGTGAGTGTGGATGGGATTGG-3',
Oct4 FP 5'-ACATCAAAGCTCTGCAGAAAGAACT-3',
Oct4 RP 5 -CTG AAT ACC TTC CCAAAT AGA ACC C-3',
Nanog FP 5'-AGAAGGCCTCAGCACCTA-3',
Nanog RP 5'-GGCCTGATTGTTCCAGGATT-3',
GAPDH FP 5'-GGTGGTCTCCTCTGACTTCAACA-3',
GAPDH RP 5'-GTTGCTGTAGCCAAATTCGTTGT-3'
Analysis of Gli1 Expression in Publicly Available Microarray
Data Set of Lung Adenocarcinoma
Gene expression profiles analyzed in this study include 22,283 probes
quantified with Affymetrix HG-U133A on 360 lung adenocarcinoma
samples from [29]. TheHarvard data from the NCIDirector’s Challenge
set was an outlier for our analysis, and hence we removed 82 samples from
the total 442 samples. Raw signal intensities for each probe set in the CEL
files were analyzed using the software package Bioconductor (http://
bioconductor.org). Expression valueswere normalized usingMAS5.0 inR.
Statistical analyses were done using R package (http://www.r-project.org/).
Kaplan-Meier and log-rank tests (for P value) were conducted to
determine whether the gene expression correlates with prognosis. A P
value of less than .05 was considered to indicate statistical significance,
and all tests were two-tailed. All the analyses were performed with
packages in R unless otherwise specified.
siRNA Transfection
Two different chemically synthesized double-stranded siRNAs for
Gli1 were purchased from Santa Cruz Biotechnologies (sc-37911)and Ambion (107670), respectively. The siRNAs were transfected at
a concentration of 100 pmol each into the cells using Oligofectamine
reagent (Invitrogen) as per manufacturer’s protocol. A non-target
siRNA (AM4635, Ambion) was used as a control for all the
transfection experiments. The cells were harvested 48 hours
posttransfection for different assays. All the siRNA experiments
were performed thrice.
Lysate Preparation and Western Blot Analysis
The cells werewashed twicewith ice-cold PBS, scraped and centrifuged
at 800 g, and lysed using M2 lysis buffer (20 mM Tris–HCl pH 6.0,
0.5% NP-40, 250 mM NaCl, 3 mM EGTA, and 3 mM EDTA)
containing protease inhibitors as described previously [30]. The protein
content was quantitated by Bradford assay (Bio-Rad). Equal amounts of
proteins (50 μg) were separated using SDS-PAGE, transferred to
nitrocellulose membranes (Bio-Rad Transblot Semi-dry), blocked with
5% nonfat dry milk in PBS with 0.1% Tween-20, and incubated with
appropriate primary antibodies; 1:3000 diluted HRP-conjugated
secondary antibodies (Pierce Biotechnology) were used and signals were
detected using ECL (GE Healthcare).
Angiogenic Tubule Formation Assay
The sorted cells were allowed to differentiate on Matrigel (BD
Biosciences) to form tubule-like structures. One hundred microliters of
thawed Matrigel was layered on the wells of 96-well tissue culture plates
followed by incubation for 60 minutes at 37°C to allow polymerization.
Sorted cells were layered (12,000 cells/100 μl ofMatrigel) on the gels and
incubated overnight at 37°C. Tubule formation was assessed in bright
field using EVOS FL microscope system, and images were acquired with
EVOS software (Life Technologies Inc., USA).
Transfections and Luciferase Assays
Sox2 proximal promoter-luciferase construct was kindly provided by
Dr. Angel G. Martin (Inbiomed, Spain) [31]. Bacterial expression
plasmid forGli1 (TCH1003) was purchased fromTransomic and further
subcloned into pcDNA3 vector. Expression plasmid for Gli2 (# 17648)
was purchased from Addgene [32]. The cells were transiently transfected
using FugeneHD (Promega) according to the manufacturer’s protocol.
Luciferase assays were carried out 48 hours posttransfection using the
dual-luciferase assay system (Promega) according to manufacturer’s
instructions. Luciferase activity was measured using a luminometer
(Turner Luminometer). For each experiment, the relative luciferase
activity was measured as the ratio of the Firefly luciferase to Renilla
luciferase, and the fold changes were calculated comparedwith the control
luciferase vector alone from at least three independent experiments.
ChIP Assays
ChIP assays were conducted on asynchronous H1650 and H1975
as previously described using indicated antibodies [30]. The
interactions at the promoter were analyzed using PCR. Each ChIP
assay was performed twice. The sequences of the ChIP PCR primers
are as follows:
FP 5'-TCCTGATTCCAGTTTGCCTC-3',
RP 5'-GGGAGAGGAGGAGGGGAG-3'
Cell Viability Assay
Cell viability was measured with thiazolyl blue tetrazolium
bromide (MTT) after 48 hours of mentioned treatment. Briefly,
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triplicates. After treatments, they were incubated with the 1mg/ml
MTT solution at 37°C for 2 hours. The reaction was terminated with
DMSO that solubilizes the formazan product formed. Absorbance at
590 nm was recorded using a plate reader.
For overexpressing Gli1 in H1650, PC-9, and HCC827 cells, they
were transiently transfected with pcDNA3-Gli1 using FugeneHD
reagent (Promega) according to the manufacturer’s protocol. The cells
were then treated with different concentrations of gefitinib and erlotinib
for 48 hours after which cell viability was tested with MTT reagent.
Statistical Analysis
The data are presented here with ± standard deviation values unless
otherwise stated. The statistical comparisons between the groups were
carried out by unpaired two-tailed Student’s t test to calculate the P value
for statistical significance. *P b .05 and **P b .01.
Results
Higher expression of Gli1 and Gli2 in cancer stem-like SP cells
Because the Hh pathway has been shown to play a significant role
in NSCLC progression and has been implicated in proliferation and
maintenance of tumor-initiating cells [17,18,22,23], we examined
the levels of the Gli transcription factors in cancer stem-like SP cells
isolated from NSCLC cell lines. A qRT-PCR showed that the levels of
Gli1 (two-fold or more) and Gli2 (1.5- to 2-fold) were significantly
higher in SP cells as compared with the nonstemlike main-population
cells from EGFR mutant H1650 and H1975 cell lines (Figure 1, A
and B). ABCG2 expression was used as a positive control, as it confers
the SP phenotype (Figure 1, A and B). Similar results were obtained
when cancer stem-like cells isolated based on aldehyde dehydrogenase
activity were analyzed by qRT-PCR. Aldhhigh cells from H1650 and
H1975 cells showed significantly higher expression of Gli1 and Gli2
in both the cell lines (Figure 1, C and D). Aldehyde dehydrogenase
(Aldh1) was used as the positive control (Figure 1, C and D).
Gli1 expression is known to mediate the induction of Hh pathway
targets, and we examined whether Gli1 expression contributes to
stem-like functions of SP cells. Towards this purpose, Gli1 was
depleted in H1650 cells using two different siRNAs; self-renewal of
SP cells was assessed by sphere-formation assays on low-adherence
plates, following established protocols [26]. Depletion of Gli1 by
siRNAs reduced the ability of SP cells to form spheres by 50%,
compared with cells transfected with a non-targeting control siRNA
(Figure 1G). Also, the size of the spheres that formed was significantly
smaller compared with the control siRNA transfected cells
(Figure 1E). These results suggested that Gli1 might be playing a
distinct role in self-renewal of NSCLC CSCs.
Cancer stem cells from glioblastoma as well as SP cells from NSCLC
cell lines have been reported to show vascular mimicry, a process in which
they can differentiate to form CD31 positive tubular structures in
Matrigel [26,33–35]. Depletion of Gli1 using two different siRNAs
abrogated the ability of SP cells to form angiogenic tubules (Figure 1F).
Thus, it appears thatGli1 plays a role inmultiple facets of SP cell function,
including self-renewal and vascular mimicry.
Correlation of Gli expression with poor patient prognosis
Given the role of Gli1 in regulating self-renewal of NSCLC
stem-like cells, we examined whether the expression of Gli genes
predicts the prognosis of lung adenocarcinoma patients. TheKaplan-Meier survival analysis was conducted on a subset of the
data from the Director’s Challenge set for Gli1, Gli2, and Gli3. It was
found that high levels of Gli1 expression correlated with poor overall
survival in patients (P = .04); however, the 5-year survival rate (P =
.4) was not significant (Figure 2, A and B). At the same time,
increased expression of Gli2 [P = .06 (overall survival) and P = .06
(5-year survival)] did not show a significant correlation with prognosis
(Figure 2, C and D). This could be reflective of the fact that Gli2
might be functioning through Gli1 and plays a secondary role in
transcriptional regulation. Increased Gli3 levels [P = .02 (overall
survival) and P = .007 (5-year survival)] also correlated with poor
disease prognosis (Figure 2, E and F) in patients. Similar
Kaplan-Meier analysis also showed that Sox2 expression predicted
poor prognosis in lung adenocarcinoma when overall survival was
examined (P = .035; data not shown). These results indicate that Gli
family of transcription factors and Sox2 might be playing an
important role in NSCLC disease progression and survival of patients.
Response of EGFR mutant NSCLC cells to exogenous
Shh protein
Embryonic stem (ES) cell transcription factors Sox2, Oct4, and
Nanog are known to play a role in maintaining stemness of CSCs
derived from various tumor types [36]. Hence, we examined whether
depletion of Gli1 affects stem-like functions of SP cells by modulating
the expression of these core ES cell transcription factors. Towards this
purpose, qRT-PCR analysis was conducted on H1650 and H1975
cells transfected two different siRNAs to Gli1 or a control,
non-targeting siRNA. It was found that the levels of all three
transcription factors were reduced upon Gli1 depletion; interestingly,
the maximal reduction was observed for Sox2 in both the cell lines
(Figure 3, A and B). Because studies from our laboratory had shown
that Sox2 plays a major role in the self-renewal properties of stem-like
SP cells [26], this result raises the possibility that Gli1 is affecting the
stem-like functions of these cells by regulating the expression of Sox2
and other factors.
Because depletion of Hh pathway effector Gli1 abrogated the
self-renewal properties of CSCs from EGFR mutant NSCLC cell
lines, we investigated if exogenous addition of SHH protein can
increase their stem-like properties. Addition of recombinant SHH
protein to sorted SP cells from H1650 and H1975 cell lines increased
their ability to form spheres in stem cell–specific media in a
dose-dependent manner (Figure 3C). Furthermore, stimulation of the
cells with recombinant SHH induced the expression of Sox2 in both
H1650 and H1975 cells, as seen by qRT-PCR (Figure 3, D and E).
Expression of Gli1 as well as FoxM1, which is a known target of Shh
signaling, also increased with the treatment; the effect on Oct4 and
Nanog was minimal (Figure 3, D and E). These results confirmed
that the EGFR mutant NSCLC cell lines are sensitive to Hh signaling
pathway and that Sox2 may be a common target gene of the EGFR
and Hh signaling pathway.
Regulation of Sox2 expression by Gli proteins
Because depletion of Gli1 transcription factor reduced the
expression of Sox2 mRNA, experiments were conducted to assess
whether Gli1 could transcriptionally induce Sox2. An examination of
the Sox2 upstream regulatory region using the Genomatix MatIn-
spector program showed the presence of multiple Gli binding sites in
Sox2 promoter/enhancer region. ChIP assays were conducted on
asynchronous H1650 and H1975 cells to assess the presence of Gli
Figure 1. Expression of Gli1 and Gli2 in CSCs from NSCLC.(A-B) Real-time PCR analysis of mRNA from SP and main-population cells
isolated from H1650 (A) and H1975 (B) cell lines reveals higher levels of Gli1 and Gli2mRNA in SP cells. ABCG2mRNA expression is used
as positive control for SP cell phenotype. (C-D) Higher levels of Gli1 and Gli2mRNA are observed in isolated Aldhhigh cells from H1650 (C)
and H1975 (D) cells. The mRNA expression of Aldehyde dehydrogenase-1 (Aldh1) is used as a positive control. (E) SP cells isolated from
H1650 cells transfected with two different Gli1 siRNAs form smaller spheres as compared with nontarget control siRNA. (F) Gli1 siRNA
treated H1650 SP cells show abrogation of formation of angiogenic tubule-like structures when grown on endothelial growth medium as
compared with control siRNA–treated H1650 SP cells. (G) The quantitation of number of spheres generated shows fewer spheres in SP
cells isolated from Gli1 siRNA–treated H1650 and H1975 cell lines as compared with the control siRNA– treated cells.
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+328) using a specific primer pair [37] (Figure 4A). The results show
that Gli1 as well as Gli2 can bind to the Sox2 proximal promoter
region (Figure 4B). Next, we carried out transient transfection assays
on H1650 and H1975 cells using a Sox2 proximal promoter
luciferase reporter construct (Sox2-luc). It was found that both Gli1
and Gli2 could efficiently induce the Sox2-luc in a dose-dependent
manner in both H1650 and H1975 cell lines; Gli1 was the stronger
inducer of Sox2 in both cell lines (Figure 4, C and D). This result,
combined with the siRNA experiment, strongly suggests that Gli1
and perhaps Gli2 can transcriptionally induce the Sox2 gene.
Our earlier studies had shown that EGFR signaling induced Sox2
expression in EGFR mutant cell lines [26]. Given this background,
we next investigated if EGF can increase the binding of the Gli
transcription factors on the Sox2 proximal promoter region. To
examine this, H1650 cells were serum starved for 24 hours and
stimulated with 100 ng/ml EGF for 18 hours. ChIP assays showed
that there was a detectable amount of Gli1 and Gli2 associated withthe promoter in serum-starved cells. Interestingly, stimulation with
EGF enhanced the binding of Gli1 to the promoter; there was no
significant increase in the binding of Gli2 to the promoter
(Figure 4E). Based on these results, we next examined if Sox2-luc
could be induced by EGF or recombinant SHH or a combination of
both EGF and SHH in H1650 and H1975, and whether such an
induction required the presence of Gli1 or Gli2. Towards this, we
transfected H1650 cells (Figure 4F) or H1975 cells (Figure 4G) with
control siRNA or siRNAs to Gli1 or Gli2 followed by transfection
with Sox2-luc. Cells were serum starved for 24 hours and then
stimulated with EGF or SHH or the combination for 18 hours.
Luciferase assays showed that stimulation with EGF or SHH induced
the Sox2-luc activity in both the cells lines; the induction was
significant in cells transfected with a control siRNA as well. A
combination treatment with EGF and SHH has an additive effect in
the Sox2-luc activity in untransfected as well as control siRNA treated
cells. Interestingly, depletion of Gli1 or Gli2 significantly abrogated
the EGF- or SHH-mediated induction of Sox2 proximal promoter
Figure 2. Kaplan-Meir survival curves for Gli family of transcription factors using the NCI Director’s Challenge set.(A-F) Kaplan-Meier
survival analysis (overall and 5-year) on the NCI Director’s Challenge data set shows poor prognosis in patients with higher mRNA
expression of Gli transcription factors. A significant correlation of poor overall survival is observed in patients with higher expression of
Gli1 transcription factor (A-B). A similar trend of poor survival is also observed for patients with higher expression of Gli2 (C-D) as well as
Gli3 (E-F) mRNA.
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mediating the induction of Sox2 downstream of both EGFR and
SHH in these NSCLC cell lines.
Cooperation of EGFR signaling and Gli1 transcription factors
to induce Sox2 expression
EGFR and Hh pathways have been reported to converge in certain
types of cancer [28,38], and the above results suggested that they
might be cooperating in the induction of Sox2 in NSCLC cells as
well. Hence, we conducted experiments to assess whether EGF can
induce Gli expression in NSCLC cells. Towards this purpose, H1650
cells were serum starved for 24 hours and stimulated with 100 ng/mlof EGF for 18 hours, and the levels of Gli1 and Gli2 were assessed by
qRT-PCR. It was found that EGF stimulation induced the levels of
Gli1 and Gli2 (~ two-fold) in H1650, H1975, and PC-9 cell lines
(Figure 5, A–C). To investigate the possibility that Gli1 is involved in
the induction of endogenous Sox2 by EGFR signaling, we depleted
Gli1 using siRNA in H1650 cells and stimulated with 100 ng/ml
EGF for 18 hours. Western blot analysis showed that Gli1 depletion
significantly reduced the EGF-mediated induction of endogenous
Sox2 and Oct4 transcription factors (Figure 5, D and F); the
induction of Sox2 by EGF was almost fully abolished, whereas the
effect on Oct4 was less pronounced. There was only a minimal effect
on Nanog expression (data not shown). This result supports the data
Figure 3. NSCLC EGFR mutant cells are responsive to exogenous SHH.(A-B) Real-time PCR analysis of two different Gli1 siRNA–
transfected H1650 (A) and H1975 (B) cells shows decrease in Sox2, Oct4, and NanogmRNA expression. (C) A higher number of spheres
are formed in the presence of increasing concentration of recombinant SHH in H1650 and H1975 SP cells as compared with untreated
control SP cells in both cell lines. (D) Real-time PCR analysis showing that recombinant SHH protein treatment increases the levels of
Sox2, Oct4, and Nanog mRNA expression. FoxM1, a known target of Hh pathway, is used as a positive control.
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possibility that EGFR and Hh signaling pathways may cooperate to
promote the induction of Sox2. To examine this hypothesis, we
pretreated H1650 cells with erlotinib that targets EGFR signaling,
and GDC-0449 and BMS 833923, which target Smoothened and
therefore the Hh pathway. Cells were pretreated with the drugs for
3 hours followed by 100 ng/ml of EGF stimulation for 18 hours.
Pretreatment with combination of EGFR inhibitor as well as Hh
inhibitor was also tested. Western blot analysis showed that treatment
with EGFR inhibitor or Smoothened inhibitors could prevent the
induction of Sox2 by EGF (Figure 5, E and G). These results further
support the observation that EGFR and Hh signaling pathways
cooperate to promote Sox2 induction and thus may be modulating
the stem-like functions of SP cells. At the same time, the possibility
exists that other molecules might also be involved in the
EGFR-mediated induction of Sox2.
Regulation of self-renewal by EGFR and Hh
signaling pathways
Given the above results, additional experiments were conducted to
assess whether EGFR and Hh signaling might cooperate to promote
stem-like functions. First, we conducted MTT assays to assess
whether two Smoothened/Hh inhibitors, GDC-0449 andBMS-833923, affect the viability of H1650 and H1975 cells. As
shown in Figure 6, A and B, 10 μM of GDC-0449 or 5 μM of
BMS-833923 reduced the viability of cells only marginally, as seen
by MTT assays. We also compared the combination of EGFR
inhibitor erlotinib with the Hh pathway inhibitors GDC-0449 or
BMS-833923; interestingly, a combination of the two reduced the
viability more effectively than each drug alone (Figure 6C). Because
depletion of Gli1 abrogated self-renewal of CSCs, we next examined
whether Hh inhibitors could affect the self-renewal of SP cells from
the EGFR mutant cell lines H1650, PC-9, and H1975. The two cell
lines H1650 and PC-9 harbor deletion in Exon 19 ΔE746-A750 in
the EGFR tyrosine kinase receptor. The H1975 cell line harbor
L858R mutation as well as the secondary T790M gatekeeper
mutation in the EGFR receptor, which makes it more resistant to
tyrosine kinase inhibitor (TKI) therapies. As shown in Figure 6D,
0.1 μMof GDC-0449 could inhibit the self-renewal of SP cells from
all the three cell lines; 500 nM gefitinib or erlotinib also had
inhibitory effect on self-renewal, but this was of a lesser magnitude
compared with GDC-0449. Interestingly, combining 0.1 μM or
1 μM of GDC-0449 with 500 nM gefitinib or erlotinib almost
completely eliminated self-renewal (Figure 6D) in all the three cell lines.
Similar cooperative effects were also observed with BMS-833923 as
well, where 1 μM BMS-833923 cooperated with 500 nM erlotinib to
Figure 4. Sox2 gene expression is regulated by Gli1 and Gli2 transcription factors.(A) A schematic representing the Sox2 proximal
promoter region and the enhancer region with potential Gli binding sites as shown by filled ellipses. (B) ChIP assays performed on H1650
and H1975 show presence of Gli1 and Gli2 on Sox2 proximal promoter region. Acetylated histone H3 (Lys9) was used as positive control
and nonspecific IgG was used as the negative control for immunoprecipitation. (C-D) The luciferase reporter assay with Sox2 proximal
promoter reporter (Sox2-luc) co-transfected Gli1 (C) and Gli2 (D) expression vector shows an increase in luciferase activity in both H1650
and H1975 cells. (E) ChIP analysis conducted on EGF-treated cells after serum starvation shows an increase in Gli1 binding to the Sox2
proximal promoter region. Serum-starved cells were used as control here. (F-G) Decrease in Sox2 proximal promoter luciferase activity
(Sox2-luc) is observed in H1650 (F) and H1975 (G) cells treated with Gli1 and Gli2 siRNA followed by EGF, recombinant SHH treatment, or
a combination of the two; treatment of untransfected cells or those transfected with nontargeting siRNA was used as control.
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cooperate with EGFR inhibitors to abrogate the self-renewal of SP cells.
Because the above results suggested that Hh pathway might be
contributing to survival and self-renewal functions mediated by
EGFR signaling, we next examined whether depletion of Gli1 could
sensitize the EGFR mutant NSCLC cells to EGFR inhibitors.Towards this purpose, H1650 or H1975 cells were transiently
transfected with a non-targeting control siRNA or a Gli1 siRNA.
Cells were subsequently treated with 500 nM erlotinib or gefitinib
(500 nM BIBW in H1975 only), and cell viability was measured by
an MTT assay. It was found that depleting Gli1 could enhance the
sensitivity of both the cell lines to EGFR inhibitors (Figure 6, F and
Figure 5. Cooperative induction of Sox2 expression by EGFR signaling and Gli proteins.(A-C) Real-time PCR analysis in serum-starved or
EGF-treated H1650 (A), H1975 (B), and PC-9 (C) cells shows increase in Gli1 and Gli2mRNA expression in EGF-treated cells as compared
with serum-starved control cells. (D) Western blot analysis with lysates from H1650 cells treated with Gli1 siRNA followed by EGF
stimulation showed a decrease in Sox2 and Oct4 protein expression as compared with EGF stimulation in control siRNA treatment.
(E) Western blot analysis on lysates from H1650 cells pretreated with either EGFR inhibitor erlotinib or the Smoothened inhibitors
GDC-0449 or BMS-833923, or a combination of the two, for 3 hours followed by EGF induction shows lower expression of Sox2 and Oct4
proteins as compared with EGF stimulation without any pretreatment. (F-G) Quantitative analysis of the Western blot in panel D (F) and
panel E (G) using ImageJ software. The data are represented as relative density calculated over the loading control actin.
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TKI-sensitive cell lines; Gli1 was transiently transfected into H1650,
PC-9, and HCC827 and subsequently treated with various
concentrations of gefitinib (1-4 μM) and erlotinib (1-4 μM)
(Figure 6, H and I). The cell viability of the treated cells measured
by MTT assays clearly demonstrated that Gli1-overexpressing cells
were more viable even in the presence of a higher concentration
(4 μM) of the drugs gefitinib and erlotinib (Figure 6, H and I).
These results suggested that Hh signaling pathway plays a role in
conferring resistance to these drugs and that targeting this pathway
might be a viable method to combat erlotinib or other EGFR
inhibitor resistance in NSCLC.Reduction in stem cell transcription factor expression with
EGFR and Gli1 inhibitor combination treatment
To further investigate the mechanisms by which Hh and EGFR
inhibition abrogates the self-renewal of NSCLC CSCs, we examined
how the inhibitors alone, or in combination, affected the expression
of stem cell transcription factors. As shown in Figure 7A, 500 nM
gefitinib or erlotinib could reduce the levels of Sox2 but had only
marginal effect onOct4 or Nanog in H1650 cells. BMS-833923 could
reduce the levels of both Gli1 and Sox2 and in combination with
EGFR inhibitors could almost completely eliminate the expression of
Sox2 (Figure 7A). Similar results were obtained in H1975 cells, which
are less sensitive to gefitinib and erlotinib (Figure 7B); the
Figure 6. EGFR and Hh pathways cooperate to modulate self-renewal.(A-B) Cell viability assays performed on H1650 and H1975 cells with
various concentrations of GDC-0449 (A) and BMS-833923 (B). (C) Cell viability assay performed on both H1650 and H1975 cells with a
combination of GDC-0449 and erlotinib or BMS-833923 and erlotinib. (D-E) Sphere assays conducted on SP cells isolated from H1650,
H1975, and PC-9 cells showed a decrease in number of spheres when treated with combination of EGFR inhibitors gefitinib or erlotinib
along with GDC-0449 (D) and BMS-833023 (E). (F-G) Cell viability assay in H1650 (F) and H1975 (G) cells treated with EGFR inhibitors after
Gli1 depletion exhibits lower viability as compared with inhibitor treatments in nontargeting control siRNA–transfected cells. (H-J) Gli1
protein transiently overexpressed in H1650 (H), PC-9 (I), and HCC827 (J) and cell viability assay performed after treating the cells with
various concentrations of gefitinib and erlotinib. Gli1 overexpression decreases the sensitivity of the cells to EGFR inhibitors and
increases cell viability.
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cantly reduce the levels of Sox2 in these cells as well (Figure 7B).
GDC-0449 could also cooperate efficiently with EGFR inhibitors in
H1650 and H1975 cells (Figure 7, C and D). These observations are
especially significant because H1975 cells are less sensitive to EGFR
inhibitors but could be sensitized by inhibiting the Hh pathway.
We next investigated the expression of Sox2 as well as Gli family
proteins Gli1 and Gli2 in HCC827 cells that were rendered resistant
to erlotinib (HCC827-ER) and PC-9 cells that were rendered
resistant to gefitinib (PC-GR), respectively [39,40], by exposure to
the drugs. Western blot experiments clearly indicated that there was
increased expression of Gli1 protein in drug-resistant cells compared
with parental cells (Figure 7, E and F). However, such a change was
not observed for Gli2 factor. Interestingly, Sox2 expression was also
elevated in both drug-resistant HCC827-ER and PC-9-GR (Figure 7,
E and F). There was no significant change in Oct4 protein expression
with in vitro–induced drug resistance in both HCC827 and PC-9
(Figure 7, E and F). These results therefore indicated that
upregulation of Gli1 and Sox2 expression conferred resistance to
EGFR TKIs in TKI-sensitive cells.
Discussion
The therapeutic strategies to treat NSCLC have multiple drawbacks
including lower efficacy of treatment and resurgence of drug-resistant
tumors [4,8]. In the past decade, the novel agents that have been used
to target the genetic alterations of NSCLC were found to be effective
in early stages of the disease, but the tumors recur by developing
alternate survival pathways [9,41]. Indeed, the escape from drug
sensitivity is one of the major hurdles facing the use of targeted
therapeutic agents. A significant amount of work has been done to
elucidate the molecular and biological mechanisms involved in drug
resistance to various targeted agents, especially the resistance to EGFR
inhibitors in the case of NSCLC [41,42]. The biopsies from NSCLC
patients who acquire resistance show that, in addition to the original
activating EGFR mutation, other mutations arose like EGFR T790M
mutation that interferes with the binding of the drugs like gefitinib or
erlotinib to the receptor, amplification of MET tyrosine kinase
receptor driving cell growth [43]. Furthermore, mutations like
amplification of EGFR or PIK3CA were also observed [43]. A small
population with acquired resistance to EGFR inhibitors displays
mutation in B-Raf gene (G469A ad V600E) [44]. Moreover,
activation of Akt/mTOR survival pathway is also observed in patients
with acquired resistance [41]. IGF-1R (insulin-like growth factor)
that is ubiquitously expressed on cancer cell surface is also implicated
in mediating resistance to EGFR inhibitor therapies [41]. In all the
cases, alternate signaling pathways were found to adapt the tumors to
flourish even in the presence of the targeted agents. Similarly, the
therapeutic strategies against the Hh pathway involving the targeting
of Smoothened (SMO) protein from the pathway resulted in drug
resistance [45,46].
It has also become clear that CSCs not only play a role in the
initiation, dormancy, and metastasis of tumors but also contribute
significantly to the drug resistance of a variety of tumors [47–49]. The
expression of various drug transporters like ABCG molecules on the
cell membrane, as well as the elevated levels of proteins including
Mcl1 and others, is thought to facilitate the survival of CSCs and
contribute to drug resistance of the resultant tumors [25,50]. In this
context, pathways that might affect the self-renewal as well as other
stem-like properties of CSCs might be good targets for combating notonly tumor growth but also drug resistance. Studies presented in this
manuscript show that the Hh signaling pathway contributes to
stem-like functions of NSCLC stem-like cells, and targeting this
pathway confers sensitivity to EGFR inhibitors.
The Hh pathway was initially identified in Drosophila as a critical
mediator of embryonic development, and it is highly conserved in
higher organisms and very active in mammalian development [19–
21,23]. It has been found that Hh pathway plays a crucial role in
tumorigenesis when reactivated in adult mammalian tissues due to
mutations or other mechanisms [18,21,51]. In this context, the
results presented here show that high Gli1 expression predicts poor
survival for lung adenocarcinoma patients, supporting the hypothesis
that this pathway contributes to the genesis and drug resistance of this
disease. Mechanistically, this could be explained by our results that
show a selective induction of Sox2 gene by Gli1 compared with other
ES cell transcription factors. Similar to Gli1, high Sox2 expression
correlates with poor prognosis of lung adenocarcinoma patients and is
known to play a clear role in stemness of lung adenocarcinoma as well
as squamous carcinoma cells. A recent study has shown that Sox2 is
amplified with PRKCI from chromosome 3q26 and enhances
stemness in lung squamous cell carcinoma [52]. The study also
showed that PKCi and Sox2 further activate Hh signaling to maintain
stem-like features in lung squamous cell carcinoma [52]. Thus, there
is a possibility of feed forward mechanism in Hh signaling mediated
regulation of CSCs.
Vascular mimicry (also termed as vasculogenic mimicry) is a
phenomenon by which tumor cells can acquire endothelial and
vascular phenotype under oxidative stress to facilitate the supply of
nutrients to the growing tumor [35,53–55]. SP cells from NSCLC as
well as glioblastoma stem cells have been shown to have the ability to
form angiogenic tubules onMatrigel, suggesting that the CSCs within
the tumors might be facilitating this phenomenon [26,33,34,56].
Although our earlier results strongly suggest that Gli1 and the Hh
pathway might be regulating self-renewal by modulating the
expression of Sox2, it is not yet clear how Gli1 and the Hh pathway
affect vascular mimicry. It is interesting that Gli1 depletion or
inhibition could prevent this process; it remains to be determined the
molecular mechanisms by which vasculogenic mimicry is regulated by
the Hh pathway. It would be of significance if it turns out that Hh
inhibitors, by their ability to inhibit vasculogenic mimicry, can also
inhibit tumor angiogenesis and might synergize with antiangiogenic
agents in therapeutic settings.
Certain recent studies in the past have suggested a cooperative
interaction between EGFR and Hh signaling in cancers, promoting
tumor growth and metastasis [28,38,57]. Our earlier studies had
shown that EGFR-Src-Akt signaling pathway could transcriptionally
induce Sox2 expression in SP cells; here we find that regulation of
Sox2 by EGFR pathway may involve its cross talk with Hh signaling
and Gli1 transcription factor [26]. EGFR-PI3k/Akt pathway is also
known to stabilize Gli proteins [38], and we have shown that
stimulating the cells with EGF led to increased expression of Gli1 and
Gli2 mRNA and protein. The present study also demonstrates a
requirement of Hh pathway and Gli1 transcription factor in
self-renewal of SP cells from EGFR–dependent NSCLC. Given this
background, the results presented here show a clear rationale for
combining Hh inhibitors with EGFR inhibitors to combat NSCLC.
Our results show that combining these inhibitors or depletion of Gli1
decreases their viability as well as self-renewal. This is especially
relevant in the case of H1975 cells, which harbor a T790M gatekeeper
Figure 7. Decrease in stem cell transcription factors with combined inhibition of EGFR signaling and Hh pathway.(A-B) Real-time PCR
analysis of mRNA expression of stem cell transcription factors like Sox2,Oct4, andNanog shows amarked decrease in their levels in both
H1650 (A) and H1975 (B) cells when treated with combination of EGFR inhibitors gefitinib and erlotinib with Smoothened inhibitor
BMS-833923. (C-D) Real-time PCR analysis of mRNA expression in H1650 (C) and H1975 (D) cells shows a similar effect on Sox2, Oct4,
and Nanog mRNA levels when the cells are treated with gefitinib or erlotinib in combination with Smoothened inhibitor GDC-0449.
(E-F) Western blot analysis with erlotinib-resistant HCC827 (HCC827-ER) and gefitinib-resistant PC-9 (PC-9-GR) shows increase in Gli1 and
Sox2 protein expression as compared with the parental cells (E). A quantitative analysis of the Western blot performed using the ImageJ
software (F). The data are represented as relative density calculated over the loading control actin.
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Hh pathway along with EGFR signaling could be a viable strategy to
combat NSCLC, especially those that harbor EGFR mutations.
Conclusions
Although the Hh pathway has been implicated in stemness and lung
cancer, the molecular mechanisms are still unclear. Our finding that
Gli1 is a strong regulator of Sox2 transcription factor thus provides a
mechanistic background to the role of Hh pathway especially in lung
adenocarcinoma. Our study clearly demonstrates that Hh pathwayand EGFR signaling cooperatively promote the stem-like functions of
tumor-initiating cells of NSCLC through Sox2 transcription factor,
and a combined therapeutic strategy may be beneficial in targeting the
cancer stem-like cells and NSCLC.
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